<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated">
      <PMID Version="1">33368026</PMID>
      <DateCompleted>
        <Year>2021</Year>
        <Month>03</Month>
        <Day>22</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2021</Year>
        <Month>03</Month>
        <Day>22</Day>
      </DateRevised>
      <Article PubModel="Print-Electronic">
        <Journal>
          <ISSN IssnType="Electronic">1179-1918</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>41</Volume>
            <Issue>2</Issue>
            <PubDate>
              <Year>2021</Year>
              <Month>Feb</Month>
            </PubDate>
          </JournalIssue>
          <Title>Clinical drug investigation</Title>
          <ISOAbbreviation>Clin Drug Investig</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Pharmacokinetics of Coadministered Viloxazine Extended-Release (SPN-812) and Methylphenidate in Healthy Adults.</ArticleTitle>
        <Pagination>
          <StartPage>149</StartPage>
          <EndPage>159</EndPage>
          <MedlinePgn>149-159</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1007/s40261-020-00992-6</ELocationID>
        <Abstract>
          <AbstractText Label="BACKGROUND AND OBJECTIVES" NlmCategory="OBJECTIVE">Viloxazine extended-release (viloxazine ER, SPN-812) is a novel non-stimulant with activity at serotonin receptors and the norepinephrine transporter, which is under investigation as a potential treatment for attention-deficit/hyperactivity disorder. Given the potential for viloxazine ER to be coadministered with other pharmacotherapies, this trial investigated the pharmacokinetics and safety of combination viloxazine ER + methylphenidate versus viloxazine ER or methylphenidate alone.</AbstractText>
          <AbstractText Label="METHODS" NlmCategory="METHODS">In this single-center, crossover, open-label trial, healthy adult participants received oral administration of 700 mg viloxazine ER alone, 36 mg methylphenidate alone, and combination viloxazine ER (700 mg) + methylphenidate (36 mg), with blood samples collected over 4 days post-administration. The active drug in viloxazine ER (viloxazine) and methylphenidate was measured using chromatographic tandem mass spectrometry. Safety assessments included adverse events (AEs), vital signs, echocardiograms, and clinical laboratory evaluations.</AbstractText>
          <AbstractText Label="RESULTS" NlmCategory="RESULTS">Of 36 healthy adults who were enrolled, 34 completed the trial. The geometric least squares mean ratios are reported as [combination/single drug (90% confidence intervals)]. For viloxazine ER, maximum measured plasma concentration (C<sub>max</sub>) = 100.98% (96.21-105.99), area under the concentration-time curve from time zero to the last measurable time (AUC<sub>t</sub>) = 98.62% (96.21-101.08), and area under the concentration-time curve from time zero to infinity (AUC<sub>∞</sub>) = 98.96% (96.55-101.44). For methylphenidate, C<sub>max</sub> = 103.55% (97.42-110.07), AUC<sub>t</sub> = 106.67% (101.01-112.64), and AUC<sub>∞</sub> = 106.61% (100.99-112.54). All reported AEs were mild in severity.</AbstractText>
          <AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Coadministration of viloxazine ER and methylphenidate did not impact the pharmacokinetics of viloxazine or methylphenidate relative to administration of either drug alone. The combination appeared to be safe and well tolerated.</AbstractText>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Faison</LastName>
            <ForeName>Shamia L</ForeName>
            <Initials>SL</Initials>
            <AffiliationInfo>
              <Affiliation>Supernus Pharmaceuticals, Inc., 9715 Key West Avenue, Rockville, MD, 20850, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Fry</LastName>
            <ForeName>Nicholas</ForeName>
            <Initials>N</Initials>
            <AffiliationInfo>
              <Affiliation>Supernus Pharmaceuticals, Inc., 9715 Key West Avenue, Rockville, MD, 20850, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Adewole</LastName>
            <ForeName>Toyin</ForeName>
            <Initials>T</Initials>
            <AffiliationInfo>
              <Affiliation>Supernus Pharmaceuticals, Inc., 9715 Key West Avenue, Rockville, MD, 20850, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Odebo</LastName>
            <ForeName>Oyinkansola</ForeName>
            <Initials>O</Initials>
            <AffiliationInfo>
              <Affiliation>Supernus Pharmaceuticals, Inc., 9715 Key West Avenue, Rockville, MD, 20850, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Schwabe</LastName>
            <ForeName>Stefan</ForeName>
            <Initials>S</Initials>
            <AffiliationInfo>
              <Affiliation>Supernus Pharmaceuticals, Inc., 9715 Key West Avenue, Rockville, MD, 20850, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Wang</LastName>
            <ForeName>Zhao</ForeName>
            <Initials>Z</Initials>
            <AffiliationInfo>
              <Affiliation>Supernus Pharmaceuticals, Inc., 9715 Key West Avenue, Rockville, MD, 20850, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Maletic</LastName>
            <ForeName>Vladimir</ForeName>
            <Initials>V</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Psychiatry/Behavioral Science, University of South Carolina School of Medicine, Greenville, SC, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Nasser</LastName>
            <ForeName>Azmi</ForeName>
            <Initials>A</Initials>
            <AffiliationInfo>
              <Affiliation>Supernus Pharmaceuticals, Inc., 9715 Key West Avenue, Rockville, MD, 20850, USA. anasser@supernus.com.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
          <PublicationType UI="D016449">Randomized Controlled Trial</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2020</Year>
          <Month>12</Month>
          <Day>23</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <MedlineTA>Clin Drug Investig</MedlineTA>
        <NlmUniqueID>9504817</NlmUniqueID>
        <ISSNLinking>1173-2563</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D000697">Central Nervous System Stimulants</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D003692">Delayed-Action Preparations</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D050484">Norepinephrine Plasma Membrane Transport Proteins</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="C493227">SLC6A2 protein, human</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>207ZZ9QZ49</RegistryNumber>
          <NameOfSubstance UI="D008774">Methylphenidate</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>5I5Y2789ZF</RegistryNumber>
          <NameOfSubstance UI="D014745">Viloxazine</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D000284" MajorTopicYN="N">Administration, Oral</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D001289" MajorTopicYN="N">Attention Deficit Disorder with Hyperactivity</DescriptorName>
          <QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000697" MajorTopicYN="N">Central Nervous System Stimulants</DescriptorName>
          <QualifierName UI="Q000008" MajorTopicYN="Y">administration &amp; dosage</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D018592" MajorTopicYN="N">Cross-Over Studies</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D003692" MajorTopicYN="N">Delayed-Action Preparations</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008774" MajorTopicYN="N">Methylphenidate</DescriptorName>
          <QualifierName UI="Q000008" MajorTopicYN="Y">administration &amp; dosage</QualifierName>
          <QualifierName UI="Q000493" MajorTopicYN="N">pharmacokinetics</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D050484" MajorTopicYN="N">Norepinephrine Plasma Membrane Transport Proteins</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D014745" MajorTopicYN="N">Viloxazine</DescriptorName>
          <QualifierName UI="Q000008" MajorTopicYN="Y">administration &amp; dosage</QualifierName>
          <QualifierName UI="Q000493" MajorTopicYN="N">pharmacokinetics</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D055815" MajorTopicYN="N">Young Adult</DescriptorName>
        </MeshHeading>
      </MeshHeadingList>
      <CoiStatement>Nicholas Fry, Toyin Adewole, Oyinkansola Odebo, Stefan Schwabe, Zhao Wang, Azmi Nasser are employees of Supernus Pharmaceuticals, Inc. Shamia L. Faison was an employee of Supernus Pharmaceuticals, Inc. at the time of this work, but is now an employee of Certara Strategic Consulting. Vladimir Maletic is an employee of the University of South Carolina School of Medicine, and is a consultant for ACADIA Pharmaceuticals Inc.; Alfasigma USA, Inc.; Alkermes, Inc.; Allergan; Eisai-Purdue; Intra-Cellular Therapies; Janssen; H. Lundbeck A/S; Otsuka America Pharmaceutical, Inc.; Sage Pharmaceuticals; Sunovion Pharmaceuticals Inc.; Supernus Pharmaceuticals, Inc.; and Takeda Pharmaceutical Company Ltd. He also serves on the speakers bureau of ACADIA Pharmaceuticals Inc.; Alkermes, Inc.; Allergan; Ironshore; Intra-Cellular Therapies; Janssen; H. Lundbeck A/S; Otsuka America Pharmaceutical, Inc.; Sunovion Pharmaceuticals Inc.; and Takeda Pharmaceutical Company Ltd; and his spouse serves on the speakers bureau of Otsuka America Pharmaceutical, Inc.</CoiStatement>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="accepted">
          <Year>2020</Year>
          <Month>11</Month>
          <Day>28</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2020</Year>
          <Month>12</Month>
          <Day>29</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2021</Year>
          <Month>3</Month>
          <Day>23</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2020</Year>
          <Month>12</Month>
          <Day>28</Day>
          <Hour>12</Hour>
          <Minute>21</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">33368026</ArticleId>
        <ArticleId IdType="pmc">PMC7886742</ArticleId>
        <ArticleId IdType="doi">10.1007/s40261-020-00992-6</ArticleId>
        <ArticleId IdType="pii">10.1007/s40261-020-00992-6</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>Singh A, Yeh CJ, Verma N, Das AK. Overview of attention deficit hyperactivity disorder in young children. Health Psychol Res. 2015;3(2):23–35. doi: 10.4081/hpr.2015.2115.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.4081/hpr.2015.2115</ArticleId>
            <ArticleId IdType="pmc">PMC4768532</ArticleId>
            <ArticleId IdType="pubmed">26973960</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Diagnostic and Statistical Manual of Mental Disorders. 5th ed. Arlington, VA: American Psychiatric Association; 2013.</Citation>
        </Reference>
        <Reference>
          <Citation>Adesman AR. The diagnosis and management of attention-deficit/hyperactivity disorder in pediatric patients. Prim Care Companion J Clin Psychiatry. 2001;3(2):66–77. doi: 10.4088/PCC.v03n0204.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.4088/PCC.v03n0204</ArticleId>
            <ArticleId IdType="pmc">PMC181164</ArticleId>
            <ArticleId IdType="pubmed">15014618</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Danielson ML, Bitsko RH, Ghandour RM, Holbrook JR, Kogan MD, Blumberg SJ. Prevalence of parent-reported ADHD Diagnosis and Associated Treatment Among U.S. Children and Adolescents, 2016. J Clin Child Adolesc Psychol. 2018;47(2):199–212. 10.1080/15374416.2017.1417860.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5834391</ArticleId>
            <ArticleId IdType="pubmed">29363986</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Simon V, Czobor P, Balint S, Meszaros A, Bitter I. Prevalence and correlates of adult attention-deficit hyperactivity disorder: meta-analysis. Br J Psychiatry. 2009;194(3):204–211. doi: 10.1192/bjp.bp.107.048827.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1192/bjp.bp.107.048827</ArticleId>
            <ArticleId IdType="pubmed">19252145</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kessler RC, Adler LA, Barkley R, Biederman J, Conners CK, Demler O, et al.  The prevalence and correlates of adult ADHD in the United States: results from the national comorbidity survey replication. Am J Psychiatry. 2006;163:716–723. doi: 10.1176/ajp.2006.163.4.716.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1176/ajp.2006.163.4.716</ArticleId>
            <ArticleId IdType="pmc">PMC2859678</ArticleId>
            <ArticleId IdType="pubmed">16585449</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Polanczyk GV, de Lima MS, Horta BL, Biederman J, Rohde LA. The worldwide prevalence of ADHD: a systematic review and metaregression analysis. Am J Psychiatry. 2007;164:942–948. doi: 10.1176/ajp.2007.164.6.942.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1176/ajp.2007.164.6.942</ArticleId>
            <ArticleId IdType="pubmed">17541055</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Turgay A, Goodman DW, Asherson P, Lasser RA, Babcock TF, Pucci ML, et al.  Lifespan persistence of ADHD: the life transition model and its application. J Clin Psychiatry. 2012;73(2):192–201. doi: 10.4088/JCP.10m06628.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.4088/JCP.10m06628</ArticleId>
            <ArticleId IdType="pubmed">22313720</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Briars L, Todd T. A review of pharmacological management of attention-deficit-hyperactivity disorder. J Pediatr Pharmacol Ther. 2016;21(3):192–206.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4956327</ArticleId>
            <ArticleId IdType="pubmed">27453697</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Catala-Lopez F, Hutton B, Nunez-Beltran A, Page MJ, Ridao M, Macias Saint-Gerons D, et al.  The pharmacological and non-pharmacological treatment of attention deficit hyperactivity disorder in children and adolescents: a systematic review with network meta-analyses of randomised trials. PLoS One. 2017;12(7):e0180355. doi: 10.1371/journal.pone.0180355.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1371/journal.pone.0180355</ArticleId>
            <ArticleId IdType="pmc">PMC5507500</ArticleId>
            <ArticleId IdType="pubmed">28700715</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Adler LA, Reingold LS, Morrill MS, Wilens TE. Combination pharmacotherapy for adult ADHD. Curr Psychiatry Rep. 2006;8:409–415. doi: 10.1007/s11920-006-0044-9.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s11920-006-0044-9</ArticleId>
            <ArticleId IdType="pubmed">16968624</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wilens T, Spencer T, Biederman J, Wozniak J, Connor D. Combined pharmacotherapy: an emerging trend in pediatric psychopharmacology. J Am Acad Child Adolesc Psychiatry. 1995;34(1):110–112. doi: 10.1097/00004583-199501000-00021.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1097/00004583-199501000-00021</ArticleId>
            <ArticleId IdType="pubmed">7860450</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Molife C, Bernauer MJ, Farr AM, Haynes VS, Kelsey D. Combination therapy patterns and predictors of ADHD in commercially insured and Medicaid populations. Postgrad Med. 2012;124(5):7–22. doi: 10.3810/pgm.2012.09.2586.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3810/pgm.2012.09.2586</ArticleId>
            <ArticleId IdType="pubmed">23095422</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Clemow DB, Bushe C, Mancini M, Ossipov MH, Upadhyaya H. A review of the efficacy of atomoxetine in the treatment of attention-deficit hyperactivity disorder in children and adult patients with common comorbidities. Neuropsychiatr Dis Treat. 2017;13:357–371. doi: 10.2147/NDT.S115707.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.2147/NDT.S115707</ArticleId>
            <ArticleId IdType="pmc">PMC5304987</ArticleId>
            <ArticleId IdType="pubmed">28223809</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Biederman J, Wilens T, Mick E, Milberger S, Spencer TJ, Faraone SV. Psychoactive substance use disorders in adults with attention deficit hyperactivity disorder (ADHD): effects of ADHD and psychiatric comorbidity. Am J Psychiatry. 1995;152:1652–1658. doi: 10.1176/ajp.152.11.1652.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1176/ajp.152.11.1652</ArticleId>
            <ArticleId IdType="pubmed">7485630</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wilens T. Impact of ADHD and its treatment on substance abuse in adults. J Clin Psychiatry. 2004;65:38–45. doi: 10.4088/JCP.v65n1003.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.4088/JCP.v65n1003</ArticleId>
            <ArticleId IdType="pubmed">15046534</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Soutullo C, DelBello MP, Ochsner JE, McElroy SL, Taylor SA, Strakowski SM, et al.  Severity of bipolarity in hospitalized manic adolescents with history of stimulant or antidepressant treatment. J Affect Disord. 2002;70:323–327. doi: 10.1016/S0165-0327(01)00336-6.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/S0165-0327(01)00336-6</ArticleId>
            <ArticleId IdType="pubmed">12128245</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Corkum P, Moldofsky H, Hogg-Johnson S, Humphries T, Tannock R. Sleep problems in children with attention-deficit/hyperactivity disorder: impact of subtype, comorbidity, and stimulant medication. J Am Acad Child Adolesc Psychiatry. 1999;38(10):1285–1293. doi: 10.1097/00004583-199910000-00018.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1097/00004583-199910000-00018</ArticleId>
            <ArticleId IdType="pubmed">10517062</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Nafees B, Setyawan J, Lloyd A, Ali S, Hearn S, Sasane R, et al.  Parent preferences regarding stimulant therapies for ADHD: a comparison across six European countries. Eur Child Adolesc Psychiatry. 2014;23(12):1189–1200. doi: 10.1007/s00787-013-0515-6.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s00787-013-0515-6</ArticleId>
            <ArticleId IdType="pmc">PMC4246123</ArticleId>
            <ArticleId IdType="pubmed">24443092</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Efron D, Jarman F, Barker M. Side effects of methylphenidate and dexamfetamine in children with attention defict hyperactivity disorder: a double-blind, crossover trial. Pediatrics. 1997;100(4):662–666. doi: 10.1542/peds.100.4.662.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1542/peds.100.4.662</ArticleId>
            <ArticleId IdType="pubmed">9310521</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Carlson GA, Kelly KL. Stimulant rebound: how common is it and what does it mean? J Child Adolesc Psychopharmacol. 2003;13(2):137–142. doi: 10.1089/104454603322163853.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1089/104454603322163853</ArticleId>
            <ArticleId IdType="pubmed">12880508</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wilens TE, Adler LA, Adams J, Sgambati S, Rotrosen J, Sawtelle R, et al.  Misuse and diversion of stimulants prescribed for ADHD: a systematic review of the literature. J Am Acad Child Adolesc Psychiatry. 2008;47(1):21–31. doi: 10.1097/chi.0b013e31815a56f1.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1097/chi.0b013e31815a56f1</ArticleId>
            <ArticleId IdType="pubmed">18174822</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yu C, Garcia-Olivares J, Candler S, Schwabe S, Maletic V. New insights into the mechanism of action of viloxazine: serotonin and norepinephrine modulating properties. J Exp Pharmacol. 2020;12:285–300. doi: 10.2147/JEP.S256586.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.2147/JEP.S256586</ArticleId>
            <ArticleId IdType="pmc">PMC7473988</ArticleId>
            <ArticleId IdType="pubmed">32943948</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Levy F. Pharmacological and therapeutic directions in ADHD: specificity in the PFC. Behav Brain Funct. 2008;4:12. doi: 10.1186/1744-9081-4-12.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1186/1744-9081-4-12</ArticleId>
            <ArticleId IdType="pmc">PMC2289834</ArticleId>
            <ArticleId IdType="pubmed">18304369</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Johnson JK, Liranso T, Saylor K, Tulloch G, Adewole T, Schwabe S, et al.  A phase II double-blind, placebo-controlled, efficacy and safety study of SPN-812 (extended-release viloxazine) in children With ADHD. J Atten Disord. 2020;24(2):348–358. doi: 10.1177/1087054719836159.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1177/1087054719836159</ArticleId>
            <ArticleId IdType="pmc">PMC6939319</ArticleId>
            <ArticleId IdType="pubmed">30924702</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Nasser A, Liranso T, Adewole T, Fry N, Hull JT, Chowdhry F, et al.  A phase 3, randomized, placebo-controlled trial to assess the efficacy and safety of once-daily SPN-812 (viloxazine extended release) in the treatment of ADHD in school-age children. Clin Ther. 2020;42(8):1452–1466. doi: 10.1016/j.clinthera.2020.05.021.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.clinthera.2020.05.021</ArticleId>
            <ArticleId IdType="pubmed">32723670</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Nasser A, Hull JT, Chowdhry F, Adewole T, Liranso T, Marcus R, et al. Extended-release viloxazine (SPN-812) 200 mg or 400 mg for the treatment of ADHD in children: Topline results of a phase 3, randomized, double-blind, placebo-controlled study (P303). 32nd Annual Psych Congress: 3–6 October 2019; San Diego, CA.</Citation>
        </Reference>
        <Reference>
          <Citation>Nasser A, Hull JT, Chowdhry F, Adewole T, Liranso T, Marcus R, et al. Extended-release viloxazine (SPN-812) 200 mg or 400 mg for the treatment of ADHD in adolescents: topline results of a phase 3, randomized, double-blind, placebo-controlled study (P302). 32nd Annual Psych Congress: 3–6 October 2019; San Diego, CA.</Citation>
        </Reference>
        <Reference>
          <Citation>Nasser A, Hull JT, Chowdhry F, Adewole T, Liranso T, Marcus R, et al. Phase 3, randomized, double-blind, placebo-controlled study evaluating efficacy and safety of extended-release viloxazine (SPN-812) for pediatric ADHD: Update on the second adolescent study (P304). 21st ASENT Annual Meeting: 25–28 March 2019; Rockville (MD).</Citation>
        </Reference>
        <Reference>
          <Citation>Concerta (Methylphenidate HCl) extended release [package insert]. Titusville, NJ: Janssen Pharmaceuticals, Inc.; 2017.</Citation>
        </Reference>
        <Reference>
          <Citation>Nasser A, Faison SL, Liranso T, Adewole T, Busse GD, Fava M, et al.  Evaluation of the effect of SPN-812 (viloxazine extended release) on QTc interval in healthy adults. J Clin Psychiatry. 2020;81(6):e1–e6. doi: 10.4088/JCP.20m13395.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.4088/JCP.20m13395</ArticleId>
            <ArticleId IdType="pubmed">33049804</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yu C. Metabolism and in vitro drug-drug interaction assessment of viloxazine. Xenobiotica. 2020;50(11):1285–1300. doi: 10.1080/00498254.2020.1767319.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1080/00498254.2020.1767319</ArticleId>
            <ArticleId IdType="pubmed">32394778</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sun Z, Murry DJ, Sanghani SP, Davis WI, Kedishvili NY, Zou Q, et al.  Methylphenidate is stereoselectively hydrolyzed by human carboxylesterase CES1A1. J Pharmacol Exp Ther. 2004;310(2):469–476. doi: 10.1124/jpet.104.067116.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1124/jpet.104.067116</ArticleId>
            <ArticleId IdType="pubmed">15082749</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>DeVane CL, Markowitz JS, Carson SW, Boulton DW, Gill HS, Nahas Z, et al.  Single-dose pharmacokinetics of methylphenidate in CYP2D6 extensive and poor metabolizers. J Clin Psychopharmacol. 2000;20(3):347–349. doi: 10.1097/00004714-200006000-00009.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1097/00004714-200006000-00009</ArticleId>
            <ArticleId IdType="pubmed">10831022</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Le Nedelec MJ, Rosengren RJ. Methylphenidate inhibits cytochrome P450 in the Swiss Webster mouse. Hum Exp Toxicol. 2002;21:273–280. doi: 10.1191/0960327102ht245oa.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1191/0960327102ht245oa</ArticleId>
            <ArticleId IdType="pubmed">12141399</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tyndale RF, Sunahara R, Inaba T, Kalow W, Gonzalez FJ, Niznik HB. Neuronal cytochrome P450IID1 (debrisoquine/sparteine-type): potent inhibition of activity by (-)-cocaine and nucleotide sequence identity to human hepatic P450 gene CYP2D6. Mol Pharmacol. 1991;40(1):63–68.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">1857341</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Spencer T, Biederman J, Wilens T, Harding M, O’Donnell D, Griffin S. Pharmacotherapy of attention-deficit hyperactivity disorder across the life cycle. J Am Acad Child Adolesc Psychiatry. 1996;35(4):409–432. doi: 10.1097/00004583-199604000-00008.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1097/00004583-199604000-00008</ArticleId>
            <ArticleId IdType="pubmed">8919704</ArticleId>
          </ArticleIdList>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
